By Colin Kellaher Merck & Co. (MRK) Wednesday said it agreed to buy Australia's Viralytics Ltd. (VLA.AU) for about $394 million in cash in a deal that expands Merck's immuno-oncology...
Proposed Acquisition of Viralytics Would Add Investigational Oncolytic Immunotherapy, CAVATAK®, Supporting Merck’s Strategy to Broaden Its Pipeline with the Best Scientific Assets Merck...
Nine OTCQX Companies to Present at 26th Annual ROTH Growth Stock Conference OTC Markets Group CEO to Speak on "IPO Readiness" Panel PR Newswire NEW YORK, March 7, 2014 NEW YORK, March...
Viralytics to present at two US institutional investor forums PR Newswire SYDNEY, March 7, 2014 SYDNEY, March 7, 2014 /PRNewswire/ -- Viralytics Limited (ASX:VLA, OTC:VRACY) will present at two...
Viralytics $27 Million Transformational Capital Raising PR Newswire SYDNEY, Jan. 30, 2014 SYDNEY, Jan. 30, 2014 /PRNewswire/ -- Highlights: Transformational capital raising of up to $27.1m at...
Target Enrollment Achieved in CAVATAK™ USA Phase 2 Melanoma Trial with Excellent Interim Results PR Newswire SYDNEY, Jan. 8, 2014 SYDNEY, Jan. 8, 2014 /PRNewswire/ -- Viralytics Limited (ASX:...
Primary Endpoint Achieved in CAVATAK Phase 2 Melanoma Trial - Primary endpoint achieved while still recruiting - Measure is immune related Progression Free Survival (irPFS) at six months after...
Viralytics Full Year Financial Results PR Newswire SYDNEY, Sept. 3, 2013 SYDNEY, Sept. 3, 2013 /PRNewswire/ -- Viralytics Limited (ASX:VLA, OTCQX:VRACY) has released its financial results for the...
Viralytics to present at 15th Annual Rodman & Renshaw Global Investment Conference PR Newswire SYDNEY, Aug. 27, 2013 SYDNEY, Aug. 27, 2013 /PRNewswire/ -- Viralytics Limited (ASX: VLA, OTCQX:...
Viralytics Ltd. Begins Trading on OTCQX® PR Newswire NEW YORK, Aug. 5, 2013 NEW YORK, Aug. 5, 2013 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.